Literature DB >> 1430230

Retinoid protection against x-ray-induced chromatid damage in human peripheral blood lymphocytes.

K K Sanford1, R Parshad, F M Price, R E Tarone, K H Kraemer.   

Abstract

Oral administration of isotretinoin (13-cis retinoic acid) was shown previously (Kraemer, K. H., J. J. DiGiovanna, A. N. Moshell, R. E. Tarone, and G. L. Peck. 1988. N. Engl. J. Med. 318:1633-1637) to reduce the frequency of skin cancers in xeroderma pigmentosum (XP) patients. The mechanism of protection was unclear. In the present study, x-ray-induced chromatid damage in PHA-stimulated blood lymphocytes from five XP patients receiving isotretinoin was approximately half that in blood samples from the same patients before or subsequent to treatment. The x-ray-induced chromatid damage in blood lymphocytes from a normal control was reduced significantly by cocultivation with blood or plasma from an XP patient receiving isotretinoin or by addition of 10(-6) M isotretinoin to cultures 1 h before x-irradiation. A similar reduction in x-ray-induced chromatid damage was reported previously by adding to the culture medium, mannitol, a scavenger of the free hydroxyl radical, or catalase, which decomposes hydrogen peroxide; both of these products are generated during ionizing radiation. The present observations suggest that isotretinoin acts as a scavenger of such radiation products, thereby providing protection against x-ray-induced chromatid damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430230      PMCID: PMC443273          DOI: 10.1172/JCI116089

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Inhibition of microsomal lipid peroxidation by 13-cis-retinoic acid.

Authors:  V M Samokyszyn; L J Marnett
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  Carrier detection in xeroderma pigmentosum.

Authors:  R Parshad; K K Sanford; K H Kraemer; G M Jones; R E Tarone
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

Review 3.  Prooxidant states and tumor promotion.

Authors:  P A Cerutti
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

4.  Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene.

Authors:  K K Sanford; R Parshad; F M Price; G M Jones; R E Tarone; L Eierman; P Hale; T A Waldmann
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

5.  Hydroperoxide-dependent cooxidation of 13-cis-retinoic acid by prostaglandin H synthase.

Authors:  V M Samokyszyn; L J Marnett
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

6.  Chemical carcinogenesis: too many rodent carcinogens.

Authors:  B N Ames; L S Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

7.  The in vitro characterization of the inhibition of mouse brain protein kinase-C by retinoids and their receptors.

Authors:  F O Cope; B D Howard; R K Boutwell
Journal:  Experientia       Date:  1986-09-15

8.  Factors affecting and significance of G2 chromatin radiosensitivity in predisposition to cancer.

Authors:  K K Sanford; R Parshad; R Gantt; R E Tarone; G M Jones; F M Price
Journal:  Int J Radiat Biol       Date:  1989-06       Impact factor: 2.694

9.  Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients.

Authors:  T C Hsu; L M Cherry; N A Samaan
Journal:  Cancer Genet Cytogenet       Date:  1985-08

10.  Radiation-induced chromatid aberrations in Cockayne syndrome and xeroderma pigmentosum group C fibroblasts in relation to cancer predisposition.

Authors:  F M Price; R Parshad; R E Tarone; K K Sanford
Journal:  Cancer Genet Cytogenet       Date:  1991-11
View more
  1 in total

Review 1.  Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer.

Authors:  H Wiseman; B Halliwell
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.